A persons genetic background plays an important role in their susceptibility to cancer, disease progression, and response to therapy. Genetic variations can be used as markers to understand complex diseases including cancer and AIDS. In collaboration with scientists at the Memorial Sloan Kettering Cancer Institute we have completed a whole genome association study of breast cancer in Ashkenazi Jewish subjects with a family history of disease. The initial scan identified a number of loci with potentially significant associations. From this data we have selected loci for follow up studies in a replication cohort. The TRIM5 gene encodes a protein involved in the protection of cells from HIV infection. We have identified regions of the human TRIM5 gene that appear to have undergone selection, perhaps in response to previous infection. Other TRIM family sequences in the human genome also appear to have been infected and may be involved in the protection to infection by other viruses. By studying variants in the complement B and C2 (CFH, C2) genes we have identified association in this gene in patients with age-related macular degeneration (AMD). AMD is the leading cause of blindness in the elderly and is estimated to effect as many as of 10 million Americans. By examining the genetic variants in the BF and C2 genes significantly protective haplotypes were identified. The complement pathway is important in the response to pathogens causative for cancer. Further study of this important component of the innate immune response could lead to insight into human disease. A deletion that removes the CFHR1 gene adjacent to CFH is highly protective for AMD. We have obtained over 3000 DNAs from subjects in the Age-Related Eye Disease Study, and are typing them for the associated markers to understand the details of the association and identify additional loci. The HH/PTCH pathway has been demonstrated to be mutated in virtually all basal cell carcinomas and a portion of medulloblastomas. In addition, many tumors display ligand-dependent activation of the HH/PTCH pathway including pancreas, prostate, gastrointestinal tract, and small cell lung tumors. The steroid-like, natural product molecule cyclopamine specifically binds to SMO, the downstream regulator of the HH/PTCH pathway. Cyclopamine has been shown to inhibit the growth of HH/PTCH-activated cell lines and xenografts. To demonstrate whether cyclopamine inhibits the expression of HH/PTCH target genes we treated prostate (DU-145, LnCaP), gastric (AGS), and breast cancer (SK-BR3) cell lines and confirmed that cyclopamine inhibits proliferation. RNA isolated from treated and untreated DU-145 cells was subjected to quantitative RT-PCR and a reduction in expression of PTCH, SMO, and GLI1, and GLI2 was observed. To further the development of HH/PTCH inhibitors we designed peptides against TM domains and intracellular loops of the SMO protein. SMO is a member of the G-protein-coupled receptor (GPCR) superfamily, and other GPCRs have been targeted by this approach. While peptides against several TM domains failed to have an effect on cell proliferation, peptides against intracellular loops 2 and 3 were potent inhibitors. As with cyclopamine, the active peptides result in a decrease in expression of HH/PTCH target genes. Both cyclopamine and SMO peptides act by eliciting apoptosis, as measured by the TUNEL assay.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Intramural Research (Z01)
Project #
1Z01BC005652-17
Application #
7592544
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
17
Fiscal Year
2007
Total Cost
$1,131,249
Indirect Cost
Name
National Cancer Institute Division of Basic Sciences
Department
Type
DUNS #
City
State
Country
United States
Zip Code
Lou, Hong; Villagran, Guillermo; Boland, Joseph F et al. (2015) Genome Analysis of Latin American Cervical Cancer: Frequent Activation of the PIK3CA Pathway. Clin Cancer Res 21:5360-70
Garrido, Claudia; Santizo, Veronica Giron; Müllers, Petra et al. (2013) Frequency of thiopurine S-methyltransferase mutant alleles in indigenous and admixed Guatemalan patients with acute lymphoblastic leukemia. Med Oncol 30:474
Boland, Joseph F; Chung, Charles C; Roberson, David et al. (2013) The new sequencer on the block: comparison of Life Technology's Proton sequencer to an Illumina HiSeq for whole-exome sequencing. Hum Genet 132:1153-63
Torimiro, Judith N; Javanbakht, Hassan; Diaz-Griffero, Felipe et al. (2009) A rare null allele potentially encoding a dominant-negative TRIM5alpha protein in Baka pygmies. Virology 391:140-7
Meyer-Lindenberg, A; Kolachana, B; Gold, B et al. (2009) Genetic variants in AVPR1A linked to autism predict amygdala activation and personality traits in healthy humans. Mol Psychiatry 14:968-75
Allikmets, Rando; Dean, Michael (2008) Bringing age-related macular degeneration into focus. Nat Genet 40:820-1
Lou, H; Dean, M (2007) Targeted therapy for cancer stem cells: the patched pathway and ABC transporters. Oncogene 26:1357-60
Remsberg, Jarrett R; Lou, Hong; Tarasov, Sergey G et al. (2007) Structural analogues of smoothened intracellular loops as potent inhibitors of Hedgehog pathway and cancer cell growth. J Med Chem 50:4534-8
O'Brien, Thomas R; Kachapati, Kritika; Zhang, Mingdong et al. (2007) HCV infection clearance with functional or non-functional caspase-12. Scand J Gastroenterol 42:416-7
Li, Xing; Gold, Bert; O'hUigin, Colm et al. (2007) Unique features of TRIM5alpha among closely related human TRIM family members. Virology 360:419-33

Showing the most recent 10 out of 40 publications